Copanlisib (Aliqopa) is a prescription medication used to treat people with certain types of lymphoma, a type of cancer. It is a type of targeted therapy, which means it works by targeting specific molecules in cancer cells. Copanlisib works by blocking a molecule called PI3K, which helps cancer cells grow and divide. By blocking this molecule, Copanlisib can stop the growth of cancer cells. Copanlisib is usually given intravenously (IV) as an infusion every two weeks for a total of six doses. Common side effects of Copanlisib include fever, chills, nausea, diarrhea, abdominal pain, and fatigue.
Copanlisib is a prescription medication classified as a phosphoinositide 3-kinase (PI3K) inhibitor. It is primarily used to treat follicular lymphoma that has relapsed or progressed after other treatments. Here's a breakdown of its key aspects:
Main use:
- Treatment of relapsed or progressive follicular lymphoma: Follicular lymphoma is a slow-growing type of non-Hodgkin lymphoma (cancer of the lymphatic system). Copanlisib is used in adults to treat this type of lymphoma when it has progressed or come back after treatment with other medications, such as chemotherapy or immunotherapy.
Mechanism of action:
- Copanlisib works by blocking the activity of an enzyme called PI3K. This enzyme plays a crucial role in cell growth and survival, and by inhibiting its activity, copanlisib can slow down the growth and spread of cancer cells.
Important points to remember:
- Copanlisib is a complex medication with significant side effects and should only be used under the supervision and guidance of a qualified healthcare professional in a hospital or specialized treatment center.
- Common side effects: These can include:
- Diarrhea
- Fatigue
- Hyperglycemia (high blood sugar)
- Pneumonia (lung infection)
- Rash
- Decreased appetite
- Mouth sores
- High blood pressure
- Serious risks: Copanlisib can also cause serious side effects, including intestinal perforation (a hole in the intestine), hepatotoxicity (liver damage), pneumonitis (inflammation of the lungs), and tumor lysis syndrome (a metabolic complication of cancer treatment).
- Not suitable for everyone: Copanlisib is contraindicated for individuals with certain medical conditions or allergies to the medication.
Additional information:
- Copanlisib is available as capsules taken orally.
- The dosage and duration of treatment are individualized based on various factors, including the patient's overall health, response to therapy, and potential side effects.
- Regular monitoring by a healthcare professional is essential during treatment to assess response, manage side effects, and adjust the treatment plan as needed.
Remember: This information is intended for general knowledge and should not be a substitute for professional medical advice. Always consult with a qualified healthcare provider for any questions or concerns regarding your individual needs and health conditions. They can provide you with personalized information and guidance about Copanlisib and its potential role in your treatment plan.